Skip to main content
Premium Trial:

Request an Annual Quote

BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection

NEW-YORK ─ BforCure recently announced it has raised €2 million ($2.3 million) from ID-Solutions to adapt its fast in vitro diagnostic PCR platform Chronos Dx to detect cancers.

Chronos Dx leverages BforCure's Fastgene technology to enable a PCR test in less than 15 minutes, the firm said.

The Paris-based point-of-care testing firm said that in the short term it aims to offer a menu of syndromic panels, and in the coming years enter cancer diagnostic testing through its partnership with ID-Solutions, a French biotech company that specializes in oncology diagnostics.

According to BforCure's website, the firm develops platforms based on microfluidics technology for numerous fields including medical diagnostics, defense and security, the food industry, and environmental protection. Fastgene technology reduces PCR cycles from minutes to seconds, the firm added.